保健品

Search documents
跨境保健品违规私域营销调查
Sou Hu Cai Jing· 2025-05-29 22:49
Core Viewpoint - The article highlights the issues surrounding the marketing and sale of overseas dietary supplements in China, particularly through private domain shopping platforms like VTN, which are often associated with misleading claims and lack of regulatory oversight [2][22][27]. Group 1: Company Overview - VTN and ABM are subsidiaries of ACCESS Group, which focuses on health and beauty products through a network of global brands and social media marketing [7]. - VTN operates as an international brand membership club for consumers, while ABM serves as a platform for light entrepreneurship, allowing individuals to become distributors without holding inventory [7][21]. Group 2: Marketing Practices - The marketing strategies employed by VTN include exaggerated claims about product efficacy, such as improving immunity and treating chronic diseases, often presented in a misleading manner [4][8]. - Distributors utilize a combination of educational content and product promotion to appeal to consumer pain points, often using social media and live streaming to reach potential buyers [8][10]. Group 3: Regulatory Issues - There are significant regulatory gaps in the oversight of cross-border e-commerce, particularly regarding the promotion of dietary supplements that are not registered or approved in China [2][22][27]. - The lack of Chinese labels on many products sold through VTN raises concerns about transparency and consumer understanding of the ingredients and potential health risks [4][22]. Group 4: Consumer Experience - Consumers face challenges in returning products purchased through VTN, as many items do not support a seven-day return policy, complicating the process of addressing quality concerns [25][26]. - Complaints regarding product quality and after-sales service have been reported, indicating a need for improved consumer protection measures in the cross-border e-commerce sector [25][26].
中国整治保健品市场“坑老”“骗老”行为
Zhong Guo Xin Wen Wang· 2025-05-28 07:25
Group 1 - The core viewpoint of the articles is that the Chinese National Market Supervision Administration is launching a special campaign to combat false advertising of drugs and health products targeting the elderly, addressing the issue of "scamming the elderly" in the market [1][2] - The campaign will focus on the increasing prevalence of online marketing tactics, such as live streaming and social media, which are being used to mislead elderly consumers through promises of free trials and exaggerated health claims [1] - Specific tasks outlined in the campaign include cracking down on misleading promotions disguised as expert consultations and health advice, as well as the sale of pseudo-high-tech products and health supplements [1] Group 2 - The campaign will enhance the regulation of advertisements related to drugs and health products for the elderly, ensuring strict adherence to advertising review systems and penalizing disguised advertisements that promote health knowledge [2] - There will be a prohibition on health products claiming to treat diseases, aiming to prevent the phenomenon of health products being marketed as "miracle drugs" [2] - Food safety supervision will be strengthened, focusing on the investigation of false information in food and health product labels, particularly regarding disease prevention and treatment claims [2]
免费鸡蛋变天价骗局!“保健品”收割老年人
Zhong Guo Xin Wen Wang· 2025-05-27 01:47
近期,多名消费者向中国新闻网《民生调查局》反映,一些看似售卖油盐酱醋米等农副产品的店铺,暗地里却偷偷向老年人销售高价"保 健品"。有老人受骗金额达数十万元。 这些老年人是如何一步步落入高价"保健品"陷阱?中国新闻网记者近期采访了多位受骗老人家属及曾经的保健品销售,还原保健培训课 堂"收割"老年人的"套路"。 花50万元买"保健品",竟包含压片糖果 硒肽、富硒植物蛋白精萃片、红曲植物甾醇硒精华片……家住北京的徐女士向中新网记者展示了自家老人四年来在"硒品优选拼团"购买 的"保健品"。据她估算,四年来,老人高价购买各类富硒产品至少花费了50万元。 "我曾亲耳听见上门服务的业务员说,有病人肝癌晚期,吃过这些'保健品'后症状缓解,暗示这些东西有医疗效果。"徐女士说。 记者注意到,徐女士展示的这些"保健品"实际并没有保健食品标识。 以其中的"希欣康红曲植物甾醇硒精华片"为例,销售人员向老人宣传该产品有保健功效,但实际该产品并没有保健品标识,包装上甚至还 写着"压片糖果"。 产品生产方恩施德源硒材料工程科技有限公司网站截图 该产品生产企业恩施德源硒材料工程科技有限公司的网站显示,该精华片是一款"专业级心脑健康呵护产品"。 ...
国泰海通|化妆品:功效保健品的机遇
国泰海通证券研究· 2025-05-23 13:05
报告导读: 新渠道、新客群有望催化保健品功效性新需求,行业迎来变革新机遇,看好 产品创新能力突出叠加强运营的品牌跑出。 文章来源 本文摘自:2025年5月22日发布的 功效保健品的机遇 訾 猛 ,资格证书编号: S0880513120002 闫清徽 ,资格证书编号:S0880522120004 李艺冰 ,资格证书编号: S0880525050001 更多国泰海通研究和服务 亦可联系对口销售获取 投资建议: 新渠道、新客群有望催化保健品功效性新需求,行业迎来变革新机遇,看好产品创新能力突出 叠加强运营的品牌跑出。 千亿保健品市场,仍具成长空间。 据欧睿数据, 2024 年我国营养健康市场规模 3998 亿同比 +3% , 其中 OTC 、运动营养、维生素及膳食补充剂( VDS )、体重管理市场规模 1441 、 63 、 2323 、 172 亿同比 +1% 、 +7% 、 +4% 、 -1% 。横向对比看, 2024 年我国运动营养、 VDS 、体重管理 市场人均消费 1 、 23 、 2 美元,较发达国家仍有提升空间,其中 VDS 人均消费约为日、韩、美的 1/3 、 1/5 、 1/5 。此外,保健品行业 ...
HH控股20250520
2025-05-20 15:24
H&H 控股 20250520 摘要 • 全球膳食补充剂(VDS)市场稳健增长,2023 年规模达 1,324 亿美元, 年均增长率 4%-5%,中国市场增速显著高于全球水平,2010 年至 2023 年复合增长率达 8%-9%,市场潜力巨大。 • 中国保健品行业受益于老龄化和新消费趋势,线上渠道转型加速,疫情后 线上占比提升至 60%,电商龙头企业如 Swisse 受益明显,竞争格局面临 调整。 • H&H 控股已转型为以成人保健为主导的保健品公司,Swisse 品牌线上渠 道收入占比超 90%,在线上市场占据领先地位,市占率稳定在 7%-8%。 • H&H 控股通过品牌矩阵延展,推出面向青少年、幼童和宠物的新品牌,如 Swisse Me、Little Swisse 和 Plus,以满足不同消费群体的需求,实现 业务多元化。 • H&H 控股积极拓展口服美容系列产品,如超光瓶、抗糖丸、烟酰胺片等, 高毛利产品有望推动盈利能力提升,并积极进行海外市场开拓,尤其是在 东南亚市场。 Q&A 保健食品具有三点定义:第一,调节机体功能;第二,不以治疗疾病为目的; 第三,对人体不会产生任何急性、亚急性或慢性伤害。因此, ...
4天3板!002365再冲涨停创近期股价新高!
Zheng Quan Ri Bao Wang· 2025-05-19 10:47
Core Viewpoint - Yong'an Pharmaceutical has seen a significant stock price increase, reaching a new high of 15.41 yuan per share, attributed to rising export prices of taurine products and strong market interest in the taurine industry [1][4]. Company Performance - As of May 19, Yong'an Pharmaceutical's stock price increased by 9.99%, with a net inflow of 182 million yuan in main funds on that day [1][2]. - Since April 1, the company's stock has risen by 86.11%, with three limit-up days in four trading sessions following a limit-up on May 14 [4]. - The company reported a net profit of 61.76 million yuan for 2024, marking a turnaround from losses [5]. Industry Context - Yong'an Pharmaceutical is a leading player in the taurine industry, holding over 50% of the global market share with an annual production capacity of 58,000 tons [4]. - The export prices for pharmaceutical-grade taurine reached 8.9 USD per kilogram and food-grade taurine at 6.89 USD per kilogram in April, indicating a significant price increase [4]. - The market has shown increased interest in the taurine supply chain, with related sectors such as health products and pet economy performing well, supporting Yong'an Pharmaceutical's stock price rise [5]. Management and Governance - The company is actively engaged in the research, production, and sales of functional foods and health products through its subsidiary, Yong'an Kangjian Pharmaceutical [5]. - There is ongoing market attention regarding the investigation of the company's chairman, which may impact operational decisions and market confidence [6].
额敏县市场监督管理局关于防范老年人药品保健品虚假宣传等问题的消费提示
Zhong Guo Shi Pin Wang· 2025-05-16 09:24
1.理性看待功效:保健食品不是药品,不能替代药物治疗疾病。如果身体有疾病,一定要及时就医,遵 循医生的建议进行治疗。2.选择正规渠道:购买药品应选择正规医院、正规药店,认准"国药准字"批准 文号;购买保健食品需认准"蓝帽子"标识,切勿通过无资质商家、流动摊贩或网络"三无"链接购买。3. 谨慎参加活动:遇到以销售为目的的健康讲座、专家义诊、免费体验等活动,务必保持高度警惕,不要 轻易购买现场推销的产品。 三、学会依法维权 (1)谨防"健康服务"变为"高价推销"。以"健康管理"名义,夸大老年人健康问题,兜售高价保健品或 器械,诱导老年人购买消费。以"会销""讲座"形式,向老年人免费赠送小礼品,或者组织旅游为诱饵, 通过洗脑式宣传、亲情攻势推销高价产品。(2)谨防"亲情牌子"变成"消费诱饵"。销售人员通过嘘寒 问暖、认"干亲"等手段或以上门服务,借家属不在场的时机逐步获取信任,诱导老年人"试用"产品,从 而推销高价产品。(3)谨防"免费陷阱"变成"连环套路"。以免费试用、低价旅游吸引老年人,再通过 恐吓式营销(如伪造体检报告)逼迫消费。以"免费体检""健康讲座""专家义诊"为名推销活动,被诱导 购买高价产品。 二、 ...
5月15日主题复盘 | 保健品概念大涨,航运继续活跃,大消费拉升
Xuan Gu Bao· 2025-05-15 08:18
据《中国食品药品监管》杂志2024年8月30日发布的《麦角硫因的功能、制备及应用研究进展》,麦角硫因是一种天然的小分子组氨酸硫脲衍生物,存在于 微生物细胞和动植物体内。EGT可由真菌、蓝细菌、放线菌等微生物合成,人体自身不能合成EGT,需通过饮食摄取,食用菌是EGT的重要饮食来源之一。 一、行情回顾 市场全天缩量调整,创业板指尾盘跌近2%。合成生物概念逆势大涨,川宁生物、洁雅股份、美农生物等多股涨停。航运板块冲高回落,宁波海运、宁波远 洋、连云港等均三连板。食品、服装、美容护理等消费股活跃,西王食品、拉芳家化、凤竹纺织等涨停。下跌方面,军工板块调整,天箭科技接近跌停;算 力概念股走弱,宏景科技跌近10%。个股跌多涨少,沪深京三市超3800股飘绿,今日成交1.19万亿。 二、当日热点 1.保健品 消息上,近日,科伦药业一则麦角硫因胶囊广告引发热议,公司董事长刘革新亲自上阵担任产品代言人,视频中其裸露上半身,肌肉线条肌理分明充满力 量。 | 股票名称 | | 最新价 = | 涨跌幅 = | 涨停时间◆ | 换手率( | 流通市值 = | | | --- | --- | --- | --- | --- | --- ...
民生健康2024年净利润9183.41万元 毛利率下降6.30个百分点
Xi Niu Cai Jing· 2025-05-09 02:44
4月25日,民生健康发布年报,2024年实现营业收入6.41亿元,同比增长10.23%;实现归母净利润9183.41万元,同比增长7.24%;实现扣非净利润8720.93万 元,同比增长10.13%;基本每股收益为0.26元/股。 2024年,民生健康毛利率为55.77%,同比下降6.30个百分点;净利率为14.32%,同比微降0.40个百分点;销售费用为1.91亿元,同比增长0.32%,主要为投入 渠道维护与品牌推广;研发费用为2398.05万元,同比下降18.87%,占营收的3.74%。 现金流方面,2024年民生健康经营活动现金流净额为1.08亿元,同比微增0.28%,经营回款能力稳定;投资活动现金流净流出2.80亿元,同比上升45.53%, 主要用于募投项目及理财产品购置;筹资活动现金流量净额为-3834万元,同比下降104%。 分业务看,2024年民生健康维生素与矿物质收入为6.21亿元,同比增长10.47%,占比为96.91%;其他保健品收入为0.12亿元,同比增长8.01%,占比为 1.93%;益生菌收入为422万元,同比下降33.74%,占比为0.66%。 2024年,民生健康取得新增授权发明 ...
新华调查丨起底新型保健品电话销售诈骗
Xin Hua She· 2025-05-06 10:51
新华社南京5月6日电 题:起底新型保健品电话销售诈骗 新华社记者朱国亮 警惕一种新型保健品电话销售诈骗——诈骗犯罪嫌疑人冒充正规保健品公司客服、医疗专家,通过电话 为购买过保健品的中老年人诊疗,一番忽悠后高价推销药品。 江苏省无锡市滨湖区人民检察院正在办理的一起案件,揭开了该类诈骗黑色链条。 众多中老年人被骗 "您好!是徐大爷吗?"2022年5月,无锡市滨湖区85岁的徐大爷接到一家保健品销售企业"健康指导老 师"的电话。因为买过该企业的药酒,效果还不错,加之对方能报出自己的姓名、住址,徐大爷便放松 了警惕。 对方主动询问徐大爷使用药酒效果如何、满意与否,继而通知徐大爷一个"好消息":知名专家"李老 师"当天将抽时间给全国20名患者电话会诊,若徐大爷同意,她可替徐大爷报名。徐大爷同意后,对方 便告知他,稍后"李老师"会给徐大爷打电话。 过了一会儿,"李老师"打来电话,很热情地关心徐大爷的病情。一阵"电话会诊"之后,"李老师"向徐大 爷推销三种药,称可治疗高血压和关节问题,保证药到病除。 "我常收看电视台这位中医专家的节目,一听'老师'声音很熟悉也就没有怀疑,最后还价到2500元成 交。药是用货到付款寄递过来的。 ...